Market Access Unlocking superpower status: The crucial role of space in sc... There has been a lot of hype around the government's plan to
News BioMarin starts rebuilding after its downsizing spree BioMarin has made its first M&A play under James Sabry, buying Inozyme to flesh out its enzyme replacement therapies (ERTs) for rare diseases.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
